Compare SCVL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCVL | KROS |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.9M | 584.9M |
| IPO Year | 1993 | 2020 |
| Metric | SCVL | KROS |
|---|---|---|
| Price | $18.81 | $18.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 496.6K | 360.2K |
| Earning Date | 03-19-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | 1.57 |
| Revenue | ★ $1,144,197,000.00 | $246,718,000.00 |
| Revenue This Year | N/A | $6,924.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $9.16 | $11.92 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $15.21 | $9.12 |
| 52 Week High | $29.76 | $22.55 |
| Indicator | SCVL | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 42.24 |
| Support Level | $18.40 | $18.33 |
| Resistance Level | $20.18 | $19.94 |
| Average True Range (ATR) | 0.76 | 0.70 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 48.45 | 15.21 |
Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual, and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs. The company operates its business as one reportable segment based on the similar nature of products sold; merchandising, distribution, and marketing processes involved; target customers; and economic characteristics of stores and e-commerce platforms. Its bricks-first, omnichannel approach provides customers easy access to a wide assortment of branded footwear for work, athletics, daily activities, and special events via a choice of delivery channels.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.